Commerzbank's 5% Sector Bounce Faces Its Own Reckoning on November 5
Silver's One-Day Pop Meets a Two-Front Test: Payrolls and Chinese Supply
HENSOLDT increases adjusted EBITDA by 33% and refines guidance for 2026 upwards
Hensoldt's Warehouse Snag Is Only Half the Story as Investors Eye Two November Milestones
D-Wave Quantum: A 44% Revenue Slide Shadows Every Technical Win
Rolls-Royce's Emirates Opening, £2.5 Billion Research Framework and Buyback All Point to One Date
CATL Lifts on Lithium Rebound as Buyback and Australian Storage Deals Broaden Its Base
Zhejiang Showcases Its Cultural and Tourism Appeal in Hamburg at Come for the Stories Event
LVMH Gains Ground as Luxury Peers Advance, Even as Baader Europe Trims Its Rating
Fluence Energy's 9.8% Pop Meets a Wall Street Reality Check
Sivers Semiconductors Drops 7.8% as Chip Sentiment Sours — But No Company News Explains the Slide
Bayer's Pharma Engine Roars While Crop Science Drags the Other Way
BYD's Bus Showcase Abroad Runs Into a European Security Question
Infineon's Gallium Nitride Bet Needs a Business Case, Not Just a Fab
Micron's Contracted Backlog Meets a Political Speed Bump
ServiceNow's NBA Deal Makes AI Tangible, but the Contract Book Is What Gets Graded
Novo Nordisk Buys Time: A 27% Profit Jump, a New CFO, and a Guidance Call Deferred to February
Mercedes-Benz Shares Climb on Sector Cheer and Post-Election Mood, Yet the Earnings Test Remains
ASADOR ETXEBARRI IS NAMED NO.1 IN THE LIST OF THE 50 BEST RESTAURANTS 2026
Vonovia's Finance Chief Exit Hands Investors a Second Variable to Watch
AMD's Record Quarter Meets a Harder Question: Who Captures the Value?
BioNTech's Raised Floor Meets a Lowered Target: Why the Street Is Cheering Two Different Things
Nvidia's Build-Out Meets Its Balance Sheet: Melius Trims Target to $315 Ahead of 17 November Results
Bourbon Princess Joins French Royal-Level Skincare Brand PinkPrincess for Global Debut
Bayer's Second China Nod Lands as Goldman and UBS Lift Their Targets
Plug Power's Political Tailwind Meets a 15% Growth Pledge That Still Needs Proving
Munich Re's 2.6% Advance Rests on Chart Strength, Not a Company Catalyst
Nurix Therapeutics stock tumbles after Sanofi ends SAR448272 program